申请人:Boehringer Ingelheim International GmbH
公开号:US08114878B2
公开(公告)日:2012-02-14
The invention relates to new dihydrothienopyrimidine of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof,
wherein X is SO or SO2, but preferably SO, and wherein R1, R2 and R3 have the meanings given in the description,
and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
本发明涉及公式1的新二氢噻唑嘧啶,以及药学上可接受的盐,对映异构体,对映体混合物,水合物或其溶剂化物。其中X为SO或SO2,但最好为SO,R1,R2和R3的含义如说明书所述,并且适用于治疗呼吸或消化不适或疾病,关节,皮肤或眼睛的炎症性疾病,周围或中枢神经系统疾病或癌症,以及包含这些化合物的制药组合物。